SA518391109B1 - Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ - Google Patents
Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـInfo
- Publication number
- SA518391109B1 SA518391109B1 SA518391109A SA518391109A SA518391109B1 SA 518391109 B1 SA518391109 B1 SA 518391109B1 SA 518391109 A SA518391109 A SA 518391109A SA 518391109 A SA518391109 A SA 518391109A SA 518391109 B1 SA518391109 B1 SA 518391109B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- cell receptors
- mammals
- reported
- mutated kras
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218688P | 2015-09-15 | 2015-09-15 | |
| PCT/US2016/050875 WO2017048593A1 (en) | 2015-09-15 | 2016-09-09 | T cell receptors recognizing hla-cw8 restricted mutated kras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA518391109B1 true SA518391109B1 (ar) | 2022-02-14 |
Family
ID=56985686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA518391109A SA518391109B1 (ar) | 2015-09-15 | 2018-03-13 | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10556940B2 (enExample) |
| EP (2) | EP3901169A1 (enExample) |
| JP (2) | JP7185524B2 (enExample) |
| KR (2) | KR20250117744A (enExample) |
| CN (2) | CN115073583A (enExample) |
| AU (3) | AU2016323017B2 (enExample) |
| CA (1) | CA2998869A1 (enExample) |
| DK (1) | DK3350213T3 (enExample) |
| ES (1) | ES2879287T3 (enExample) |
| IL (1) | IL257840B2 (enExample) |
| MX (1) | MX2018003062A (enExample) |
| SA (1) | SA518391109B1 (enExample) |
| SG (1) | SG10201913868XA (enExample) |
| WO (1) | WO2017048593A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2557123B (en) | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| LT3494133T (lt) * | 2016-08-02 | 2022-12-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t ląstelės receptoriai |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EP3602053B1 (en) * | 2017-03-31 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of isolating neoantigen-specific t cell receptor sequences |
| EP3635000A4 (en) * | 2017-05-16 | 2021-04-14 | The Johns Hopkins University | Manabodies and methods of using |
| WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| SG11202002425PA (en) * | 2017-09-20 | 2020-04-29 | The United States Of America As Represented By The Secretary | Hla class ii-restricted t cell receptors against mutated ras |
| AU2018345400B2 (en) | 2017-10-05 | 2024-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| CN111836638B (zh) * | 2017-12-04 | 2024-10-29 | 美国卫生和人力服务部 | 针对突变的ras的hla i类限制性t细胞受体 |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| US12331097B2 (en) * | 2018-08-16 | 2025-06-17 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
| CN113412277B (zh) * | 2019-01-22 | 2025-07-18 | 美国卫生和人力服务部 | 针对含有g12r突变的ras的hla第ii类限制性t细胞受体 |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| US20220175899A1 (en) * | 2019-04-11 | 2022-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| US20210342750A1 (en) * | 2019-08-14 | 2021-11-04 | Nec Corporation | Information processing apparatus, information processing method, and storage medium |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| WO2021163477A1 (en) * | 2020-02-14 | 2021-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against ras with g12v mutation |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| EP4182029A1 (en) * | 2020-07-16 | 2023-05-24 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class ii-restricted drb t cell receptors against ras with g12v mutation |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| US20240175047A1 (en) | 2021-02-25 | 2024-05-30 | Alaunos Therapeutics, Inc. | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN114920824B (zh) * | 2022-05-27 | 2023-12-05 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301017B2 (en) * | 2002-05-30 | 2007-11-27 | Kolesnick Richard N | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| ES2842878T3 (es) * | 2005-08-05 | 2021-07-15 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Generación de células T específicas de antígeno |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| EP2618835B1 (en) | 2010-09-20 | 2017-07-05 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SI2755997T1 (sl) * | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| PL3223850T3 (pl) | 2014-11-26 | 2020-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptory limfocytów t przeciwko zmutowanemu kras |
-
2016
- 2016-09-09 EP EP21162567.8A patent/EP3901169A1/en active Pending
- 2016-09-09 CA CA2998869A patent/CA2998869A1/en active Pending
- 2016-09-09 SG SG10201913868XA patent/SG10201913868XA/en unknown
- 2016-09-09 KR KR1020257025325A patent/KR20250117744A/ko active Pending
- 2016-09-09 CN CN202111083392.9A patent/CN115073583A/zh active Pending
- 2016-09-09 EP EP16770408.9A patent/EP3350213B1/en active Active
- 2016-09-09 JP JP2018513423A patent/JP7185524B2/ja active Active
- 2016-09-09 IL IL257840A patent/IL257840B2/en unknown
- 2016-09-09 CN CN201680058891.3A patent/CN108350059B/zh active Active
- 2016-09-09 DK DK16770408.9T patent/DK3350213T3/da active
- 2016-09-09 WO PCT/US2016/050875 patent/WO2017048593A1/en not_active Ceased
- 2016-09-09 AU AU2016323017A patent/AU2016323017B2/en active Active
- 2016-09-09 ES ES16770408T patent/ES2879287T3/es active Active
- 2016-09-09 KR KR1020187010326A patent/KR102841067B1/ko active Active
- 2016-09-09 US US15/758,954 patent/US10556940B2/en active Active
- 2016-09-09 MX MX2018003062A patent/MX2018003062A/es unknown
-
2018
- 2018-03-13 SA SA518391109A patent/SA518391109B1/ar unknown
-
2020
- 2020-01-10 US US16/739,310 patent/US11667692B2/en active Active
-
2021
- 2021-02-10 AU AU2021200833A patent/AU2021200833B2/en active Active
-
2022
- 2022-07-26 AU AU2022209229A patent/AU2022209229B2/en active Active
- 2022-11-25 JP JP2022188263A patent/JP7461445B2/ja active Active
-
2023
- 2023-05-01 US US18/310,141 patent/US20230406904A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| MX2024005678A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| CR20240019A (es) | RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150) | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
| MX384919B (es) | Receptores de células t de kras anti-mutado. | |
| CY1122720T1 (el) | Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii | |
| MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
| CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
| CY1123385T1 (el) | Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης | |
| CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| PH12018501335A1 (en) | Novel generation of antigen-specific tcrs | |
| MX2018013081A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
| CL2022002208A1 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación | |
| MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
| TR201905447T4 (tr) | Yeni mhc bağımsız tümörle ilişkili antijenler. | |
| WO2016077525A3 (en) | Human anti-thyroglobulin t cell receptors | |
| MX2017005644A (es) | Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas. | |
| BR112017003108A8 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno |